Skip to main content

Advertisement

Log in

The effect of raloxifene, a SERM, on extracellular matrix protein expression of pelvic fibroblasts

International Urogynecology Journal Aims and scope Submit manuscript

Abstract

Introduction and hypothesis

We hypothesize that the abnormal extracellular matrix (ECM) turnover in pelvic tissues of women with prolapse may be attenuated by raloxifene. We examine the effect of raloxifene on ECM protein expression in pelvic fibroblasts.

Methods

Pelvic fibroblasts were isolated from cases (N = 6) and controls (N = 3). Cells were treated with raloxifene. Dose–response analyses were performed by ANOVA. mRNA and protein expression of collagen I, III, MMPs, and TIMPs were determined by RT-PCR and Western blot. MMP activity was analyzed by zymography.

Results

The mRNA expression of TIMP-3 and protein expression of TIMP-1 and TIMP-3 were significantly increased by raloxifene in fibroblasts from both cases and controls (P < 0.05). Collagen I, III, and MMP mRNA and protein expressions were not affected.

Conclusions

Raloxifene selectively attenuates abnormal matrix degradation by increasing inhibitors of proteases, TIMPs, in pelvic fibroblasts. This opens the possibility for SERMs to be used as preventive therapy for pelvic floor disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Olsen AL, Smith VJ, Bergstrom JO, Colling JC, Clark AL (1997) Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstet Gynecol 89:501–506

    Article  PubMed  CAS  Google Scholar 

  2. Chen BH, Wen Y, Li H, Polan ML (2002) Collagen metabolism and turnover in women with stress urinary incontinence and pelvic prolapse. Int Urogynecol J Pelvic Floor Dysfunct 13:80–87, discussion 87

    Article  PubMed  CAS  Google Scholar 

  3. Cox DA, Helvering LM (2006) Extracellular matrix integrity: a possible mechanism for differential clinical effects among selective estrogen receptor modulators and estrogens? Mol Cell Endocrinol 247:53–59

    Article  PubMed  CAS  Google Scholar 

  4. Hendrix SL, Cochrane BB, Nygaard IE, Handa VL, Barnabei VM, Iglesia C et al (2005) Effects of estrogen with and without progestin on urinary incontinence. JAMA 293:935–948

    Article  PubMed  CAS  Google Scholar 

  5. Goldstein SR, Nanavati N (2002) Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study. Am J Obstet Gynecol 187:521–527

    Article  PubMed  CAS  Google Scholar 

  6. Hendrix SL, McNeeley SG (2001) Effect of selective estrogen receptor modulators on reproductive tissues other than endometrium. Ann N Y Acad Sci 949:243–250

    Article  PubMed  CAS  Google Scholar 

  7. Goldstein SR, Johnson S, Watts NB, Ciaccia AV, Elmerick D, Muram D (2005) Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen. Menopause 12:160–164

    Article  PubMed  Google Scholar 

  8. Bump RC, Mattiasson A, Bo K, Brubaker LP, DeLancey JO, Klarskov P et al (1996) The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol 175:10–17

    Article  PubMed  CAS  Google Scholar 

  9. Chen B, Wen Y, Wang H, Polan ML (2003) Differences in estrogen modulation of tissue inhibitor of matrix metalloproteinase-1 and matrix metalloproteinase-1 expression in cultured fibroblasts from continent and incontinent women. Am J Obstet Gynecol 189:59–65

    Article  PubMed  CAS  Google Scholar 

  10. Surazynski A, Jarzabek K, Haczynski J, Laudanski P, Palka J, Wolczynski S (2003) Differential effects of estradiol and raloxifene on collagen biosynthesis in cultured human skin fibroblasts. Int J Mol Med 12:803–809

    PubMed  CAS  Google Scholar 

  11. Chen B, Wen Y, Polan ML (2004) Elastolytic activity in women with stress urinary incontinence and pelvic organ prolapse. Neurourol Urodyn 23:119–126

    Article  PubMed  Google Scholar 

  12. Carneiro E, Menezes R, Garlet GP, Garcia RB, Bramante CM, Figueira R et al (2009) Expression analysis of matrix metalloproteinase-9 in epithelialized and nonepithelialized apical periodontitis lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 107:127–132

    Article  PubMed  Google Scholar 

  13. Chang CJ, Hsu LA, Ko YH, Chen PL, Chuang YT, Lin CY et al (2009) Thrombin regulates matrix metalloproteinase-9 expression in human monocytes. Biochem Biophys Res Commun 385:241–246

    Article  PubMed  CAS  Google Scholar 

  14. Lan YQ, Zhang C, Xiao JH, Zhuo YH, Guo H, Peng W et al (2009) Suppression of IkappaBalpha increases the expression of matrix metalloproteinase-2 in human ciliary muscle cells. Mol Vis 15:1977–1987

    PubMed  CAS  Google Scholar 

  15. Mitsui N, Suzuki N, Koyama Y, Yanagisawa M, Otsuka K, Shimizu N et al (2006) Effect of compressive force on the expression of MMPs, PAs, and their inhibitors in osteoblastic Saos-2 cells. Life Sci 79:575–583

    Article  PubMed  CAS  Google Scholar 

  16. Noh EM, Kim JS, Hur H, Park BH, Song EK, Han MK et al (2009) Cordycepin inhibits IL-1beta-induced MMP-1 and MMP-3 expression in rheumatoid arthritis synovial fibroblasts. Rheumatology (Oxford) 48:45–48

    Article  CAS  Google Scholar 

  17. Rolfe KJ, Irvine LM, Grobbelaar AO, Linge C (2007) Differential gene expression in response to transforming growth factor-beta1 by fetal and postnatal dermal fibroblasts. Wound Repair Regen 15:897–906

    Article  PubMed  Google Scholar 

  18. Victory R, Saed GM, Diamond MP (2007) Antiadhesion effects of docosahexaenoic acid on normal human peritoneal and adhesion fibroblasts. Fertil Steril 88:1657–1662

    Article  PubMed  CAS  Google Scholar 

  19. Wen Y, Polan ML, Chen B (2006) Do extracellular matrix protein expressions change with cyclic reproductive hormones in pelvic connective tissue from women with stress urinary incontinence? Hum Reprod 21:1266–1273

    Article  PubMed  CAS  Google Scholar 

  20. Maquoi E, Munaut C, Colige A, Lambert C, Frankenne F, Noel A et al (2002) Stimulation of matrix metalloproteinase-9 expression in human fibrosarcoma cells by synthetic matrix metalloproteinase inhibitors. Exp Cell Res 275:110–121

    Article  PubMed  CAS  Google Scholar 

  21. Mott JD, Werb Z (2004) Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 16:558–564

    Article  PubMed  CAS  Google Scholar 

  22. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP (1997) Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74:111–122

    PubMed  CAS  Google Scholar 

  23. Weber AM, Buchsbaum GM, Chen B, Clark AL, Damaser MS, Daneshgari F et al (2004) Basic science and translational research in female pelvic floor disorders: proceedings of an NIH-sponsored meeting. Neurourol Urodyn 23:288–301

    Article  PubMed  Google Scholar 

  24. Helvering LM, Adrian MD, Geiser AG, Estrem ST, Wei T, Huang S et al (2005) Differential effects of estrogen and raloxifene on messenger RNA and matrix metalloproteinase 2 activity in the rat uterus. Biol Reprod 72:830–841

    Article  PubMed  CAS  Google Scholar 

  25. Liu YM, Choy KW, Lui WT, Pang MW, Wong YF, Yip SK (2006) 17Beta-estradiol suppresses proliferation of fibroblasts derived from cardinal ligaments in patients with or without pelvic organ prolapse. Hum Reprod 21:303–308

    Article  PubMed  CAS  Google Scholar 

  26. Gebhart JB, Rickard DJ, Barrett TJ, Lesnick TG, Webb MJ, Podratz KC et al (2001) Expression of estrogen receptor isoforms alpha and beta messenger RNA in vaginal tissue of premenopausal and postmenopausal women. Am J Obstet Gynecol 185:1325–1330, discussion 1330–1321

    Article  PubMed  CAS  Google Scholar 

  27. Schwartz LB, Rutkowski N, Horan C, Nachtigall LE, Snyder J, Goldstein SR (1998) Use of transvaginal ultrasonography to monitor the effects of tamoxifen on uterine leiomyoma size and ovarian cyst formation. J Ultrasound Med 17:699–703

    PubMed  CAS  Google Scholar 

  28. Goldstein SR, Neven P, Zhou L, Taylor YL, Ciaccia AV, Plouffe L (2001) Raloxifene effect on frequency of surgery for pelvic floor relaxation. Obstet Gynecol 98:91–96

    Article  PubMed  CAS  Google Scholar 

  29. Clark AL, Slayden OD, Hettrich K, Brenner RM (2005) Estrogen increases collagen I and III mRNA expression in the pelvic support tissues of the rhesus macaque. Am J Obstet Gynecol 192:1523–1529

    Article  PubMed  Google Scholar 

  30. Irie T, Takahata M, Majima T, Abe Y, Komatsu M, Iwasaki N et al (2010) Effect of selective estrogen receptor modulator/raloxifene analogue on proliferation and collagen metabolism of tendon fibroblast. Connect Tissue Res 51:179–187

    Article  PubMed  CAS  Google Scholar 

Download references

Funding

This work was supported by the National Institute of Aging at the National Institutes of Health [RO1 AG01790] and the Mary Lake Polan Transition Fund of the Stanford University School of Medicine.

Conflicts of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yan Wen.

Additional information

Jung Han Lee and Yan Wen contributed equally as first authors.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, J.H., Wen, Y., Polan, M.L. et al. The effect of raloxifene, a SERM, on extracellular matrix protein expression of pelvic fibroblasts. Int Urogynecol J 23, 349–355 (2012). https://doi.org/10.1007/s00192-011-1567-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00192-011-1567-0

Keywords

Navigation